Table 2 Univariate and multivariate Cox proportional hazards model for overall survival and postoperative cumulative recurrence

From: Ubiquitin-specific protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination

 

Overall survival

Cumulative recurrence

 

Univariate

Multivariate

Univariate

Multivariate

Factors

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Sex (female vs. male)

0.507 (0.202−1.271)

0.147

0.575 (0.174−1.895)

0.363

Age, years (>50 vs. ≤50)

0.627 (0.378−1.066)

0.085

0.616 (0.297−1.278)

0.193

Tumor differentiation (III/IV vs. I/II)

2.140 (1.194−3.835)

0.011

1.300 (0.682−2.479)

0.425

2.094 (0.919−4.768)

0.078

  

Tumor encapsulation (absent vs. present)

0.957 (0.551−1.662)

0.877

1.295 (0.622−2.695)

0.489

Tumor size (diameter, cm) (>5 vs. ≤5)

5.483 (3.002−10.014)

<0.001

3.412 (1.733−6.718)

<0.001

7.086 (2.778−18.069)

<0.001

4.119 (1.491−11.380)

0.006

Tumor number (multiple vs. single)

1.597 (0.893−2.856)

0.114

1.126 (0.481−2.639)

0.784

Vascular invasion (yes vs. no)

4.915 (2.769−8.724)

<0.001

4.554 (2.429−8.536)

<0.001

10.266 (3.829−27.522)

<0.001

8.706 (2.977−25.458)

<0.001

Liver cirrhosis (yes vs. no)

0.763 (0.452–1.289)

0.312

0.697 (0.339−1.433)

0.327

HBsAg (+ vs. −)

1.083 (0.463−2.534)

0.853

0.805 (0.280−2.317)

0.687

Serum AFP, ng/mL (>20 vs. ≤20)

2.739 (1.425−5.262)

0.002

1.403 (0.649−3.033)

0.389

3.900 (1.340−11.355)

0.013

2.168 (0.656−7.157)

0.204

Serum ALT, U/L (>75 vs. ≤75)

2.062 (0.926−4.594)

0.077

1.860 (0.646−5.361)

0.250

Serum TB, μmol/L (>17 vs. ≤17)

0.585 (0.311−1.099)

0.095

0.490 (0.198−1.212)

0.122

USP4 expression (high vs. low)

4.076 (2.106−7.887)

<0.001

3.099 (1.510−6.357)

0.002

4.802 (1.760−13.099)

0.002

3.354 (1.123−10.031)

0.030

  1. CI confidence interval, HR hazard ratio